primary analysis of the RANDOMIZED eortc-2139/columbus-ad trial: Adjuvant encorafenib and binimetinib versus placebo in high-risk stage II BRAF-V600E/K melanoma.

Eur J CancerJul 21, 2026 (epub)
Clinical ResearchOncology (Medical)

Alexander Cj van Akkooi, Michal Kicinski, Anne-Sophie Govaerts et al.

✦ AI-curated · Sources linked

In 30 seconds

The EORTC 2139 - Columbus-AD trial evaluated the efficacy and safety of adjuvant therapy with encorafenib and binimetinib versus placebo in patients with resected high-risk stage IIB/C BRAF V600E/K melanoma. This randomized controlled trial included 110 patients, revealing a 12-month recurrence-free survival (RFS) of 86% in the treatment group compared to 70% in the placebo group.

Key findings

  • 12-month recurrence-free survival was 86% for encorafenib and binimetinib versus 70% for placebo.
  • Distant metastasis-free survival at 12 months was 92% for the treatment group compared to 82% for placebo.
  • 24% of patients experienced grade ≥3 treatment-related adverse events with the combination therapy.

Why it matters

This study highlights the potential benefit of adjuvant BRAF/MEK inhibitor therapy in reducing recurrence risk in high-risk melanoma patients, which may influence treatment strategies in this population.

Source

PubMed · PMID 42501621

Published in Eur J Cancer. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Oncology (Medical)

Clinical ResearchPreventive Medicine / Public Health

2025 National Guidelines on the Mediterranean Diet: Executive Summary of a Joint Report by Italian Scientific Societies and the National Institute of Health Task Force on Clinical Practice Guidelines.

This systematic review and practice guideline, developed by a multidisciplinary panel using NUTRIGRADE, assessed Mediterranean diet evidence across nine health domains and one economic domain.

Nutr RevNov 12, 2026Read summary
Clinical ResearchOrthopedic Surgery

Prevention of Venous Thromboembolism after Total Hip or Knee Replacement.

This multicenter randomized comparative-effectiveness noninferiority trial compared 30 days of aspirin, warfarin, or rivaroxaban for VTE prophylaxis after elective total hip or knee arthroplasty.

N Engl J MedNov 12, 2026Read summary
Clinical ResearchAnesthesiology

Effect of discontinuing antihypertensives on perioperative hypotension in older patients before non-cardiac surgery: multicentre, randomised, double blind, controlled trial.

This multicentre, randomised, double blind, placebo controlled trial assessed whether withholding ACE inhibitors or ARBs on the morning of surgery reduces perioperative hypotension in older adults undergoing non-cardiac…

BMJNov 11, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.